Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,550,700.00 in Stock

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $103.38, for a total value of $1,550,700.00. Following the transaction, the director now owns 2,056,931 shares of the company’s stock, valued at approximately $212,645,526.78. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $107.12, for a total value of $1,606,800.00.
• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $101.68, for a total value of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $109.06, for a total value of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total value of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $108.54, for a total value of $1,628,100.00.

Moderna Price Performance

Shares of Moderna stock opened at $101.41 on Friday. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $144.43. The business has a fifty day simple moving average of $100.63 and a 200 day simple moving average of $93.64.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. During the same period in the previous year, the firm earned $3.61 earnings per share. The firm’s quarterly revenue was down 44.9% compared to the same quarter last year. Sell-side analysts predict that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on MRNA shares. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. Canaccord Genuity Group lifted their price objective on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research report on Friday, February 23rd. HSBC reiterated a “reduce” rating and issued a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a research report on Thursday, March 28th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Moderna currently has an average rating of “Hold” and an average target price of $126.49.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRNA. ICA Group Wealth Management LLC acquired a new position in Moderna in the fourth quarter valued at about $27,000. First Pacific Financial bought a new stake in shares of Moderna in the third quarter valued at about $27,000. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Moderna in the fourth quarter valued at about $27,000. Arlington Trust Co LLC lifted its holdings in shares of Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares in the last quarter. Finally, Westside Investment Management Inc. bought a new stake in shares of Moderna in the first quarter valued at about $32,000. 75.33% of the stock is owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.